Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of HL-085 plus vemurafenib in BRAF V600E/V600K-mutant advanced melanoma
CTR20211726Phase 2Active
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib, vemurafenib in melanoma, sponsored by Shanghai KeChow Pharmaceuticals. Started Oct 2021; status: active.
02
Drugs
tunlametinibvemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20211726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211726.